Latest Analyst Reports On Aspen Aerogels, Inc.
Recently stock market analysts have updated their consensus ratings on shares of Aspen Aerogels, Inc. (NYSE:ASPN).
Most recent broker ratings
04/14/2016 – KeyBanc began new coverage on Aspen Aerogels, Inc. giving the company a “overweight” rating. They now have a USD 7 price target on the stock.
11/06/2015 – Aspen Aerogels, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 8.5 price target on the stock.
09/11/2015 – Aspen Aerogels, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 9.5 price target on the stock.
08/26/2015 – Aspen Aerogels, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 10 price target on the stock.
08/12/2015 – Global Hunter Securities began new coverage on Aspen Aerogels, Inc. giving the company a “buy” rating. They now have a USD 13 price target on the stock.
05/12/2015 – Aspen Aerogels, Inc. was upgraded to “strong-buy” by analysts at Zacks. They now have a USD 8 price target on the stock.
03/13/2015 – Aspen Aerogels, Inc. had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 10.5 price target on the stock.
02/17/2015 – Aspen Aerogels, Inc. was upgraded to “outperform” by analysts at Robert W. Baird. They now have a USD 11 price target on the stock.
10/16/2014 – Evercore ISI began new coverage on Aspen Aerogels, Inc. giving the company a “buy” rating. They now have a USD 17 price target on the stock.
Aspen Aerogels, Inc. has a 50 day moving average of 4.43 and a 200 day moving average of 5.27. The stock’s market capitalization is 92.62M, it has a 52-week low of 3.38 and a 52-week high of 9.03.
The share price of the company (NYSE:ASPN) was down -1.10%, with a high of 4.52 during the day and the volume of Aspen Aerogels, Inc. shares traded was 40200.
View other investors thoughts on Aspen Aerogels, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.